The estimation power of alternative comorbidity indices
- PMID: 18489502
- DOI: 10.1111/j.1524-4733.2008.00343.x
The estimation power of alternative comorbidity indices
Abstract
Objective: Health-care expenditures are strongly influenced by overall illness burden. Appropriate risk adjustment is required for correct policy analysis. We compared three risk adjustment methods: the Charlson comorbidity index (CCI), the chronic disease score (CDS), and the Agency for Healthcare Research and Quality's comorbidity index (AHRQCI) in terms of their estimation power in analyzing health-care expenditures.
Method: Data from the Thomson MarketScan Research Databases (Thomson Healthcare, Ann Arbor, MI) were used to estimate total health-care expenditures of migraine patients treated by a triptan. Seven distinct multivariate models were evaluated for model fit (CCI only, CDS only, AHRQCI only, CCI + CDS, CCI + AHRQCI, CDS + AHRQCI, and CCI + CDS + AHRQCI). The estimation power of these indices (alone and in combination) was evaluated using Bayesian and Akaike information criteria, log-likelihood scores, and pseudo R(2) values.
Results: Confirming results from previous studies, when comorbidity indices were considered individually the results were inconclusive. Statistically the best performance was observed in the model that included all three of the comorbidity measures (CCI + CDS + AHRQCI); however, the practical differences in the estimated values were small.
Conclusion: Low correlation between these comorbidity indices shows that it is possible to have potential risk factors that are not captured in the single comorbidity index. Each comorbidity measure considers different risks, and the collinearity of the three measures is not strong enough to preclude using them simultaneously in the same model.
Similar articles
-
Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.Pharmacoepidemiol Drug Saf. 2020 Mar;29(3):279-287. doi: 10.1002/pds.4938. Epub 2019 Dec 11. Pharmacoepidemiol Drug Saf. 2020. PMID: 31828875
-
ASA grade and Charlson Comorbidity Index of spinal surgery patients: correlation with complications and societal costs.Spine J. 2014 Jan;14(1):31-8. doi: 10.1016/j.spinee.2013.03.011. Epub 2013 Apr 17. Spine J. 2014. PMID: 23602377
-
Patterns of use and health expenses associated with triptans among adults with migraines.Clin J Pain. 2015 Aug;31(8):673-9. doi: 10.1097/AJP.0000000000000152. Clin J Pain. 2015. PMID: 25185875
-
Which risk-adjustment index performs better in predicting 30-day mortality? A systematic review and meta-analysis.J Eval Clin Pract. 2015 Apr;21(2):292-9. doi: 10.1111/jep.12307. Epub 2015 Feb 6. J Eval Clin Pract. 2015. PMID: 25659330 Review.
-
Burden of migraine and impact of emerging therapies on managed care.Am J Manag Care. 2019 Jan;25(2 Suppl):S35-S39. Am J Manag Care. 2019. PMID: 30681822 Review.
Cited by
-
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.Acta Oncol. 2024 Apr 9;63:137-146. doi: 10.2340/1651-226X.2024.20337. Acta Oncol. 2024. PMID: 38591349 Free PMC article.
-
Use of Open Claims vs Closed Claims in Health Outcomes Research.J Health Econ Outcomes Res. 2023 Sep 5;10(2):44-52. doi: 10.36469/001c.87538. eCollection 2023. J Health Econ Outcomes Res. 2023. PMID: 37692913 Free PMC article.
-
Maternal Early-Life Risk Factors and Later Gestational Diabetes Mellitus: A Cross-Sectional Analysis of the UAE Healthy Future Study (UAEHFS).Int J Environ Res Public Health. 2022 Aug 19;19(16):10339. doi: 10.3390/ijerph191610339. Int J Environ Res Public Health. 2022. PMID: 36011972 Free PMC article.
-
Levothyroxine Treatment of Pregnant Women with Hypothyroidism: Retrospective Analysis of a US Claims Database.Adv Ther. 2020 Feb;37(2):933-945. doi: 10.1007/s12325-020-01223-2. Epub 2020 Jan 18. Adv Ther. 2020. PMID: 31955358 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
